Oxford Nanopore Technologies announces £25 million ($41 million) fundraising
Oxford Nanopore Technologies Ltd. announced that it has raised £25 million ($41 million) in new funding via a private placement of ordinary shares in the Company.
The funds will support further development, external technology validation and production capabilities for the Company’s proprietary technology for molecular analysis applications that include DNA sequencing and protein analysis. In addition to the development of techniques using biological nanopores, Oxford Nanopore has also strengthened existing projects and collaborations in the development of solid-state nanopores.
The round was funded by existing and new institutional and individual investors from the US and UK, including Lansdowne Partners, IP Group, Invesco Perpetual, Redmile Group, Illumina and other undisclosed investors. The Company has previously raised £49 million since its formation in 2005.
“We are delighted to welcome several exceptional new investors and thank our existing high-calibre shareholders for their ongoing support as we continue to develop the next generation of molecular analysis system,” said Dr Gordon Sanghera, CEO of Oxford Nanopore.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.